ViGenCell Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cost of Revenue	-79.37	0.84	3.45	2.9
Gross Profit	134.87	-0.84	-3.45	-2.9
Selling, General & Admin	3,231	3,449	4,774	5,303
Research & Development	12,830	15,452	12,285	6,819
Other Operating Expenses	84.6	91.64	115.69	73.82
Operating Expenses	17,284	20,084	18,210	13,133
Operating Income	-17,149	-20,084	-18,214	-13,136
Interest Expense	-357.83	-399.27	-289.2	-352.68
Interest & Investment Income	3,332	2,248	1,219	99.41
Currency Exchange Gain (Loss)	8.25	0.79	-8.35	1.29
Other Non Operating Income (Expenses)	-909.44	0.32	-1.7	2,105
EBT Excluding Unusual Items	-15,076	-18,234	-17,294	-11,283
Gain (Loss) on Sale of Investments	-8.88	358.85	35.43	168.77
Gain (Loss) on Sale of Assets	-273.42	-	-135.12	-
Pretax Income	-15,358	-17,875	-17,393	-11,114
Net Income	-15,358	-17,875	-17,393	-11,114
Net Income to Common	-15,358	-17,875	-17,393	-11,114
Shares Outstanding (Basic)	19	19	19	17
Shares Outstanding (Diluted)	19	19	19	17
Shares Change (YoY)	0.87%	0.43%	10.20%	-
EPS (Basic)	-799.80	-937.29	-915.91	-645.96
EPS (Diluted)	-799.80	-937.29	-916.00	-758.98
Free Cash Flow	-14,412	-16,244	-24,743	-19,477
Free Cash Flow Per Share	-750.52	-851.73	-1302.97	-1130.20
EBITDA	-13,257	-15,987	-15,296	-11,417
D&A For EBITDA	3,892	4,098	2,918	1,718
EBIT	-17,149	-20,084	-18,214	-13,136
Advertising Expenses	-	2.54	17	13

Source: S&P Capital IQ. Standard template. Financial Sources.